MedTrace Logo

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

NCT04777162 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-03-04

No results posted yet for this study

Summary

Immunotherapy acquired resistance was observed in clinical practice. The investigators intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.

Conditions

Interventions

DRUG

Tislelizumab

For included participants, tislelizumab would be administrated 200mg q3w iv.

DRUG

Anlotinib

Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.

Sponsors & Collaborators

  • Peking University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2023-01-31
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04777162 on ClinicalTrials.gov